News Sanofi showcases eczema data ahead of EU decision Dupixent predicted to be blockbuster for Sanofi
News Pfizer’s eczema drug Eucrisa approved Pfizer has gained FDA approval for Eucrisa, a new eczema treatment which could achieve peak annual sales of $2 billion a year.
News Chiesi signs $1.9bn deal to buy KalVista and its HAE drug Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
